With an increase in the number of immuno-oncology drugs coming to market, the question of sustainability cannot be ignored. Biopharma companies are looking for reimbursement deals that reflect the value of their innovations, while healthcare systems are concerned about rising costs. Through an examination of the PD-1/LD1 market for Europe, consulting firm Charles River Associates takes a deeper look into the reimbursement and access issues that novel immunotherapies face, focusing on three crucial areas. Find out what they are in this essential In Vivo article.